Gewinn- und Verlustrechnung von Merck & Co., Inc.

This article was written by Doug Nathman, with research by his team at Trefis.

JEPI's 8% monthly yield looks like an obvious win over SCHD's modest payout, but the IRS treats those two income streams in ways that can quietly flip the comparison depending on where you hold them.

MRK's growing pipeline, acquired assets and new product launches are gaining traction as it builds a diversified growth base ahead of Keytruda's 2028 LOE.

For years, Moderna, Inc‘s (NASDAQ:MRNA) biggest challenge wasn't developing new medicines — it was convincing investors that it could thrive after COVID-19. The company's vaccine transformed it into one of the world's most recognizable biotech names, but as the pandemic demand faded, so did its revenue and stock price.

JNJ's diversified portfolio and pipeline strength offer an edge over MRK as both face patent expiration challenges.

Moderna jumped 177% on a cancer-vaccine first, plus retail's reversal

Ascent Group LLC grew its holdings in shares of Merck and Co., Inc. (NYSE: MRK) by 11.1% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 41,325 shares of the company's stock after buying an additional 4,135 shares during the

Merck (MRK), the pharmaceutical giant behind Keytruda, dipped roughly 0.5% to $151.39 Thursday afternoon after blasting 12.6% higher Wednesday. That tiny retrea

Merck and Moderna's personalized melanoma therapy meet key goals in phase III study, improving recurrence-free and distant metastasis-free survival in high-risk patients.

Moderna (MRNA) shares are paring back some of their recent gains on Thursday morning – but a Morgan Stanley analyst believes Merck (MRK) stock remains a buy following blockbuster cancer drug trial results. A recent late-stage clinical trial showcased a combination therapy comprising MRNA's intismeran autogene and MRK's renowned Keytruda as effective in high-risk patients with melanoma.